Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
Authors
Oxana V. Crysler
Rogel Cancer Center, University of Michigan, Ann Arbor, MI;
Oxana V. Crysler , Mark Yarchoan , Junji Furuse , Peter R. Galle , Wattana Sukeepaisarnjaroen , Nguyen Tien Thinh , Gianluca Masi , Ho Yeong Lim , Maria Varela , Charu Gupta , Mallory Makowsky , Alejandra Negro , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03298451
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 551)
DOI
10.1200/JCO.2023.41.4_suppl.551
Abstract #
551
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
First Author: Bruno Sangro
Poster
2021 ASCO Annual Meeting
T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
First Author: Patricia McCoon
Poster
2021 Gastrointestinal Cancers Symposium
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
First Author: Xuyang Song
Poster
2018 ASCO Annual Meeting
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
First Author: Ghassan K. Abou-Alfa